WO2001009361A1 - Hsv-1 recombinant et vaccins viraux actifs - Google Patents

Hsv-1 recombinant et vaccins viraux actifs Download PDF

Info

Publication number
WO2001009361A1
WO2001009361A1 PCT/IL2000/000469 IL0000469W WO0109361A1 WO 2001009361 A1 WO2001009361 A1 WO 2001009361A1 IL 0000469 W IL0000469 W IL 0000469W WO 0109361 A1 WO0109361 A1 WO 0109361A1
Authority
WO
WIPO (PCT)
Prior art keywords
sep
hsv
dna
recombinant virus
gene
Prior art date
Application number
PCT/IL2000/000469
Other languages
English (en)
Inventor
Yechiel Becker
Yael Asher
Sergey Bujanover
Tamir Ben-Hur
Gholamreza Darai
Roland Kehm
Michal Moyal
Angela Rosen-Wolff
Original Assignee
Yissum Research Development Company Of The Hebrew University Of Jerusalem
Hadasit Medical Research Services & Development Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew University Of Jerusalem, Hadasit Medical Research Services & Development Company, Ltd. filed Critical Yissum Research Development Company Of The Hebrew University Of Jerusalem
Priority to AU63130/00A priority Critical patent/AU6313000A/en
Priority to CA 2381056 priority patent/CA2381056A1/fr
Priority to IL14784100A priority patent/IL147841A0/xx
Priority to EP20000949877 priority patent/EP1210448A1/fr
Priority to JP2001513617A priority patent/JP2003505103A/ja
Publication of WO2001009361A1 publication Critical patent/WO2001009361A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un herpès simplex virus recombinant dont le génome a été altéré par des mutations ou des délétions dans les gènes uniques de petite taille 8 et 12. L'invention concerne également des vaccins comprenant ledit herpès simplex virus recombinant.
PCT/IL2000/000469 1999-08-03 2000-08-03 Hsv-1 recombinant et vaccins viraux actifs WO2001009361A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU63130/00A AU6313000A (en) 1999-08-03 2000-08-03 Recombinant hsv-1 and live viral vaccines
CA 2381056 CA2381056A1 (fr) 1999-08-03 2000-08-03 Hsv-1 recombinant et vaccins viraux actifs
IL14784100A IL147841A0 (en) 1999-08-03 2000-08-03 Recombinant hsv-1 and live viral vaccines
EP20000949877 EP1210448A1 (fr) 1999-08-03 2000-08-03 Hsv-1 recombinant et vaccins viraux actifs
JP2001513617A JP2003505103A (ja) 1999-08-03 2000-08-03 組換えｈｓｖ−１および生ウイルスワクチン

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13121299A IL131212A0 (en) 1999-08-03 1999-08-03 Recombinant virus and live-virus vaccines
IL131212 1999-08-03

Publications (1)

Publication Number Publication Date
WO2001009361A1 true WO2001009361A1 (fr) 2001-02-08

Family

ID=11073099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000469 WO2001009361A1 (fr) 1999-08-03 2000-08-03 Hsv-1 recombinant et vaccins viraux actifs

Country Status (6)

Country Link
EP (1) EP1210448A1 (fr)
JP (1) JP2003505103A (fr)
AU (1) AU6313000A (fr)
CA (1) CA2381056A1 (fr)
IL (1) IL131212A0 (fr)
WO (1) WO2001009361A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092708A1 (fr) * 2002-05-02 2003-11-13 Institute Of Gene And Brain Science Agents antitumoraux utilisant le hsv
EP1385937A1 (fr) * 2001-04-20 2004-02-04 Chiron Corporation Apport d'agents polynucleotides au systeme nerveux central
GB2374873B (en) * 2000-01-21 2004-05-26 Biovex Ltd Herpes virus strains
EP2059255A2 (fr) * 2006-09-08 2009-05-20 The Trustees of the University of Pennsylvania Vaccins contre le hsv-1 et le hsv-2 et méthodes d'utilisation
US7592169B2 (en) 2003-04-25 2009-09-22 Medimmune, Llc Methods and compositions for treatment and prevention of HSV-2 infections and conditions
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
CN102657861A (zh) * 2010-08-16 2012-09-12 郑州金森生物科技工程有限公司 单纯疱疹病毒ⅰ型基因重组减毒活疫苗及其制备方法
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
US9284355B2 (en) 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
CN113710259A (zh) * 2019-03-14 2021-11-26 国家儿童医院研究所 作为有效的癌症疗法的合胞溶瘤性单纯疱疹突变体
WO2021253733A1 (fr) * 2020-06-16 2021-12-23 Dongguan Hec Biopharmaceutical R&D Co., Ltd. Construction et son utilisation

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704632T3 (es) 2011-09-08 2019-03-19 Univ New York Virus de herpes simplex oncolítico y sus usos terapéuticos
WO2016205429A1 (fr) 2015-06-15 2016-12-22 New York University Méthode de traitement utilisant des virus oncolytiques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013943A1 (fr) * 1991-01-31 1992-08-20 Smithkline Beecham Biologicals S.A. Variantes par deletion du virus-1 de l'herpes et vaccins
WO1998015637A1 (fr) * 1996-05-22 1998-04-16 The University Of Pittsburgh Of The Commonwealth System Of Higher Education Souches du virus de l'herpes
WO1998051809A1 (fr) * 1997-05-12 1998-11-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Vecteurs multigenes derives de hsv

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013943A1 (fr) * 1991-01-31 1992-08-20 Smithkline Beecham Biologicals S.A. Variantes par deletion du virus-1 de l'herpes et vaccins
WO1998015637A1 (fr) * 1996-05-22 1998-04-16 The University Of Pittsburgh Of The Commonwealth System Of Higher Education Souches du virus de l'herpes
WO1998051809A1 (fr) * 1997-05-12 1998-11-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Vecteurs multigenes derives de hsv

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BROWN S M ET AL: "THREE MUTANTS OF HERPES SIMPLEX VIRUS TYPE 2 ONE LACKING THE GENES US-10 US-11 AND US-12 AND TWO IN WHICH R-S HAS BEEN EXTENDED BY 6 KB TO 0.91 MAP UNITS WITH LOSS OF U-S SEQUENCES BETWEEN 0.94 AND THE U-S-TR-S JUNCTION", JOURNAL OF GENERAL VIROLOGY, vol. 68, no. 1, 1987, pages 1 - 18, XP000943860, ISSN: 0022-1317 *
CASSADY KEVIN A ET AL: "The second-site mutation in the herpes simplex virus recombinants lacking the gamma1 34.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha.", JOURNAL OF VIROLOGY, vol. 72, no. 9, 1998, pages 7005 - 7011, XP000943826, ISSN: 0022-538X *
LONGNECKER R ET AL: "GENERATION OF AN INVERTING HERPES SIMPLEX VIRUS 1 MUTANT LACKING THE L-S JUNCTION ALPHA SEQUENCES AN ORIGIN OF DNS SYNTHESIS AND SEVERAL GENES INCLUDING THOSE SPECIFYING GLYCOPROTEIN E AND THE ALPHA-47 GENE", JOURNAL OF VIROLOGY, vol. 58, no. 2, 1986, pages 583 - 591, XP000944184, ISSN: 0022-538X *
MOYAL MICHAL ET AL: "Mutations in the UL53 gene of HSV-1 abolish virus neurovirulence to mice by the intracerebral route of infection.", VIRUS RESEARCH, vol. 26, no. 2, 1992, pages 99 - 112, XP000943857, ISSN: 0168-1702 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8277818B2 (en) 2000-01-21 2012-10-02 Biovex Limited Herpes virus strains for gene therapy
GB2374873B (en) * 2000-01-21 2004-05-26 Biovex Ltd Herpes virus strains
US7223593B2 (en) 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
US10301600B2 (en) 2000-01-21 2019-05-28 Biovex Limited Virus strains
US8680068B2 (en) 2000-01-21 2014-03-25 Biovex Limited Herpes virus strains
EP1385937A1 (fr) * 2001-04-20 2004-02-04 Chiron Corporation Apport d'agents polynucleotides au systeme nerveux central
EP1385937A4 (fr) * 2001-04-20 2005-11-09 Chiron Corp Apport d'agents polynucleotides au systeme nerveux central
US7384627B2 (en) 2002-05-02 2008-06-10 Institute Of Gene And Brain Science Antitumor agents with the use of HSV
WO2003092708A1 (fr) * 2002-05-02 2003-11-13 Institute Of Gene And Brain Science Agents antitumoraux utilisant le hsv
US7592169B2 (en) 2003-04-25 2009-09-22 Medimmune, Llc Methods and compositions for treatment and prevention of HSV-2 infections and conditions
AU2007292905B2 (en) * 2006-09-08 2013-05-23 The Trustees Of The University Of Pennsyvania HSV-1 and HSV-2 vaccines and methods of use thereof
US9492533B2 (en) 2006-09-08 2016-11-15 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
EP2059255A2 (fr) * 2006-09-08 2009-05-20 The Trustees of the University of Pennsylvania Vaccins contre le hsv-1 et le hsv-2 et méthodes d'utilisation
EP2059255A4 (fr) * 2006-09-08 2011-08-31 Univ Pennsylvania Vaccins contre le hsv-1 et le hsv-2 et méthodes d'utilisation
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
US8871223B2 (en) 2006-09-08 2014-10-28 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
US8911747B2 (en) 2006-09-08 2014-12-16 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
US9284355B2 (en) 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
CN102657861A (zh) * 2010-08-16 2012-09-12 郑州金森生物科技工程有限公司 单纯疱疹病毒ⅰ型基因重组减毒活疫苗及其制备方法
CN113710259A (zh) * 2019-03-14 2021-11-26 国家儿童医院研究所 作为有效的癌症疗法的合胞溶瘤性单纯疱疹突变体
EP3937960A4 (fr) * 2019-03-14 2023-03-29 Research Institute at Nationwide Children's Hospital Mutants d'herpès simplex oncolytique syncytiaux en tant qu'agents thérapeutiques anticancéreux puissants
WO2021253733A1 (fr) * 2020-06-16 2021-12-23 Dongguan Hec Biopharmaceutical R&D Co., Ltd. Construction et son utilisation

Also Published As

Publication number Publication date
EP1210448A1 (fr) 2002-06-05
CA2381056A1 (fr) 2001-02-08
JP2003505103A (ja) 2003-02-12
AU6313000A (en) 2001-02-19
IL131212A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
KR100372934B1 (ko) 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신
Turin et al. BHV-1: new molecular approaches to control a common and widespread infection
Matsumura et al. An equine herpesvirus type 1 recombinant with a deletion in the gE and gI genes is avirulent in young horses
Kimman et al. Inactivation of glycoprotein gE and thymidine kinase or the US3-encoded protein kinase synergistically decreases in vivo replication of pseudorabies virus and the induction of protective immunity
Da Costa et al. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease
MORRISON et al. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1
Spector et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs
JPH08507784A (ja) ウイルス・ワクチン
WO2001009361A1 (fr) Hsv-1 recombinant et vaccins viraux actifs
Abendroth et al. Varicella‐zoster virus immune evasion
Ghiasi et al. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein
JP4044131B2 (ja) ヘルペスウイルスワクチン
Kinchington Latency of varicella zoster virus; a persistently perplexing state
Brehm et al. Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more α-genes: ICP4, ICP27, ICP22, and ICP0
US20040185056A1 (en) Vaccines containing bovine herpesvirus 1 attenuated by mutation in latency-related gene
JP5177927B2 (ja) ｇＭ陰性ＥＨＶ変異体
US11305009B2 (en) Recombinant virus with diminished latency and methods of using same
Boldogköi et al. Replication and virulence of early protein 0 and long latency transcript deficient mutants of the Aujeszky′ s disease (pseudorabies) virus
ES2324406T3 (es) Mutantes de herpesvirus equino (ehv) gm-negativos sin elementos heterologos.
Thompson et al. Partial rescue of herpes simplex virus neurovirulence with a 3.2 kb cloned DNA fragment
Holman et al. Neurovirulent factor ICP34. 5 uniquely expressed in the herpes simplex virus type 1 Δγ 1 34.5 mutant 1716
Aricò et al. Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection
Ahn et al. Properties of an equine herpesvirus 1 mutant devoid of the internal inverted repeat sequence of the genomic short region
Goodman et al. Identification, transfer, and characterization of cloned herpes simplex virus invasiveness regions
US7374768B1 (en) Viral vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 147841

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2381056

Country of ref document: CA

Ref document number: 63130/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000949877

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000949877

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 2000949877

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000949877

Country of ref document: EP